SynthesisEuropean journal of medical research2025
Evaluation of intraovarian injection of platelet-rich plasma for enhanced ovarian function and reproductive success in women with POI and POR: a systematic review and meta-analysis.
Synthesis in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The Value of Platelet-Rich Plasma Treatment in Reproductive Disorders: An Umbrella Review.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Pooled it
- Efficacy of intraovarian autologous platelet-rich plasma in women with poor ovarian reserve or ovarian insufficiency: a meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2026Pooled it
- Platelet-rich plasma and folliculogenesis: a systematic mechanistic review and computational pathway analysis.Frontiers in reproductive health · 2026Pooled it
- Granulocyte colony-stimulating factor treatment in women with premature ovarian insufficiency: a pilot clinical study of biological activity and menstrual resumption.Reproductive biology and endocrinology : RB&E · 2026Trial
- Evaluation of the Effect of Platelet-Rich Plasma on the Outcome of IVF Cycle in Patients with Poor Ovarian Response.JBRA assisted reproduction · 2026Article
- Bilateral ovarian abscesses following platelet-rich plasma injection for "ovarian rejuvenation": a case report.F&S reports · 2026Article
- Research progress on blood therapy for anti-aging.Journal of advanced research · 2026Review
- The immune microenvironment: a key regulator of ovarian function during ovarian aging.Frontiers in immunology · 2026Review
- Clinical Strategies for Counteracting Human Ovarian Aging: Molecular Background, Update, and Outlook.International journal of molecular sciences · 2025Review
- Premature Ovarian Insufficiency and Diminished Ovarian Reserve: From Diagnosis to Current Management and Treatment.Journal of clinical medicine · 2025Review
- Ovarian aging: pathophysiology and recent developments in maintaining ovarian reserve.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to evaluate the effect of the intraovarian injection of platelet-rich plasma (PRP) on ovarian reserve and reproductive outcomes in patients with premature ovarian insufficiency (POI) and poor ovarian response (POR). METHODS AND DATA SOURCES: The study registered in the PROSPERO database adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. PubMed, Web of Science, Scopus, Google Scholar, and ClinicalTrials.gov databases were searched from inception to June 2024-23 studies included in the meta-analysis. A total of 1853 participants aged 29.8-45 years old were included in the meta-analysis. The human studies reporting the effect of intraovarian PRP injection on ovarian reserve indicators were included in the meta-analysis. The quality of the included studies was assessed using the Cochrane Handbook or the Newcastle-Ottawa scale. The primary outcomes were serum levels of anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), Estradiol, and antral follicle count (AFC), number of retrieved oocytes, metaphase II (M2) oocytes, and pregnancy and live birth rates. RESULT(S): The pooled analysis of the included studies showed that intraovarian PRP injection significantly increased oocyte number (WMD: 0.97, 95% CI 0.58, 1.35, P < 0.001), M2 oocyte number (WMD: 0.80, 95% CI 0.33, 1.27, P < 0.001), AFC (WMD: 1.64, 95% CI 0.90, 2.38, P < 0.001), and AMH levels (WMD: 0.12 ng/mL, 95% CI 0.07, 0.17, P < 0.001) in women with POR. Besides, in women with POI, PRP injection significantly improved AFC (WMD: 1.33, 95% CI 1.19, 1.47, P < 0.001) and serum levels of FSH (WMD: - 15.68 IU/mL, 95% CI - 24.12, - 7.24, P < 0.001), AMH (WMD: 0.29 ng/mL, 95% CI 0.08, 0.49, P = 0.006), and LH (WMD: - 9.87 IU/mL, 95% CI - 15.23, - 4.51, P < 0.001). The meta-analysis revealed a pregnancy ratio of 0.21 and a live birth ratio of 0.18 in women with poor ovarian reserve after PRP injection. In women with POI, the figures were marginally lower, recorded as 0.138 for pregnancy and 0.10 for live birth, respectively.
conclusionPRP may serve as an alternative therapy for POI and POR; however, further investigation is required to validate its efficacy and determine suitable candidates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.